INCY · 10-Q · 2026Q3 · Full report

OPZELURA Demand and Markets

INCYTE CORP · 2026-10-29 · Importance 33 · Surprise 24 · From source text

Excluding the one-time $246.0 million CMS-related sales benefit, OPZELURA’s nine-month net sales increase was driven by $141.6 million of higher volume, partly offset by an $11.2 million price decrease. U.S. patient demand increased in both atopic dermatitis and vitiligo, while third-quarter sales also reflected volume and price increases of $48.5 million and $18.4 million, respectively. Sales outside the U.S. were $46.9 million for the quarter and $126.4 million for the first nine months, up from $44.4 million and $100.2 million in the comparable 2025 periods. International growth was primarily driven by continued uptake in Canada and Italy and entry into new markets; inventory remained within the normal range at quarter-end.

Key facts

• OPZELURA sales outside the U.S. were $46.9 million for the three months and $126.4 million for the nine months ended September 30, 2026, compared with $44.4 million and $100.2 million, respectively, in the 2025 periods. source
• Excluding the $246.0 million settlement-related impact, OPZELURA net sales for the nine months ended September 30, 2026 increased by $141.6 million from volume and decreased by $11.2 million from price compared with the corresponding 2025 period. source
• OPZELURA net sales increased by $48.5 million from volume and $18.4 million from price in the three months ended September 30, 2026, compared with the corresponding 2025 period. source
• OPZELURA's volume increase was primarily due to increased U.S. patient demand in both atopic dermatitis and vitiligo. source
• Growth in OPZELURA sales outside the U.S. in both periods was primarily driven by continued uptake in Canada and Italy, as well as entry into new markets. source
• OPZELURA inventory levels were within normal range at the end of the third quarter of 2026. source

Impact estimates